ReviewInternational journal of preventive medicine2026
Cost Effectiveness of Diagnosis and Screening Methods in Nonalcoholic Fatty Liver Disease: A Systematic Review.
Review in International journal of preventive medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease that is emerging and spreading worldwide. This condition manifests as a hepatic component of the metabolic syndrome, and its occurrence is closely associated with risk factors such as insulin resistance and abdominal obesity. This study aims to review and analyze the cost-effectiveness of diagnostic and screening methods for NAFLD through a systematic review. Methods: Searches were conducted in Web of science, Scopus, Pubmed, Embase, National Health Services Economic Evaluation Database, Cochrane Database of Systematic Reviews; DAHTA-Database. NHS Health Technology assessment (Centre for review and. DISSEMMINATION Library-CRD), Cost Effectiveness Analysis Registry. The search covered articles published between January 1990 and December 2023. Studies that were written in English and Persian and examined the cost-utility and cost-effectiveness of diagnosis and screening methods in NAFLD were included in our review. Data extraction was guided by the Consolidated Health Economic Evaluation Reporting Standards checklist, and the quality of economic evaluations was assessed using the Criteria for Health Economic Quality Evaluation tool. All costs were converted to 2024 U.S. dollars using Purchasing Power Parity. Results: The search yielded 1649 studies, and 11 studies were eligible for inclusion. The studies were mainly based on a European setting and then Asian and American alike. Most of the studies used different decision analysis models such as decision tree and Markov to evaluate the cost-effectiveness. The lowest and highest numerical values of outcome measures were 0.021 and 14.46 quality-adjusted life years, respectively. Furthermore, the lowest and highest numerical value of the cost of diagnosis and screening methods in NAFLD were $101, and $123,706, respectively. Conclusions: Policymakers, decision-makers, and healthcare professionals should consider not only the acceptability, accuracy, sensitivity, accessibility, and feasibility of NAFLD screening and diagnostic strategies but also their cost-effectiveness and affordability, taking into account the financial burden of the disease and local and national cost-effectiveness data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.